Macrolactam immunomodulators for topical treatment of inflammatory skin diseases

Journal of the American Academy of Dermatology
E C BornhövdAndreas Wollenberg

Abstract

The immunomodulatory macrolactams provide an alternative to glucocorticosteroids for the topical treatment of atopic dermatitis and other inflammatory dermatoses. Tacrolimus (FK506), as well as the newer ascomycin derivative ASM 981 (pimecrolimus), penetrate the inflamed epidermis and are suitable for topical therapy. Both substances inhibit the transcription of proinflammatory cytokine genes such as interleukin 2, which are dependent on the nuclear factor NF-AT. They block the catalytic function of calcineurin, which leads to the inhibition of the transport of the cytoplasmic component of NF-AT to the cell nucleus. Multicenter, randomized, double-blind clinical trials with topical formulations have shown the efficacy of both substances in moderate to severe atopic dermatitis. A review is presented of the biochemical and cell biologic properties, mode of action, pharmacokinetic data, side effects, results of the clinical trials, and further indications for tacrolimus and ASM 981, along with an overview of the related substances cyclosporine and sirolimus (rapamycin).

Citations

Nov 2, 2002·The British Journal of Dermatology·K A FeldmannH Wolfe
May 15, 2013·The World Allergy Organization Journal·Ulf DarsowUNKNOWN European Task Force on Atopic Dermatitis / EADV Eczema Task Force
Jul 24, 2013·Expert Opinion on Drug Metabolism & Toxicology·Hanna PruchaClaudia Traidl-Hoffmann
Feb 26, 2014·The Journal of Allergy and Clinical Immunology. in Practice·Peter D ArkwrightUNKNOWN Atopic Dermatitis Working Group of the Allergic Skin Diseases Committee of the AAAAI
Jul 31, 2010·Immunology and Allergy Clinics of North America·Andreas Wollenberg, Christina Schnopp
Apr 14, 2007·Dermatologic Clinics·Neal Bhatia
Aug 26, 2004·Dermatologic Therapy·David E Cohen, Noushin Heidary
Apr 29, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·U DarsowUNKNOWN European Task Force on Atopic Dermatitis
Apr 15, 2004·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M L PacorR Corrocher
Apr 22, 2004·The British Journal of Dermatology·L Esquivel-PedrazaR Orozco-Topete
Apr 22, 2004·The British Journal of Dermatology·J DissemondM Goos
Apr 19, 2003·Journal of the European Academy of Dermatology and Venereology : JEADV·J C Prinz
May 17, 2008·CNS Neuroscience & Therapeutics·Germán Sierra-Paredes, Germán Sierra-Marcuño
May 3, 2007·International Journal of Dermatology·Tugba OskayLale Kutluay
Oct 22, 2008·International Journal of Dermatology·C O MensingH Mensing
Aug 12, 2008·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Andreas WollenbergThomas Ruzicka
Sep 27, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·T OppelA Wollenberg
Jul 11, 2006·BJOG : an International Journal of Obstetrics and Gynaecology·D M Luesley, G P Downey
Jul 19, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·J RingUNKNOWN Global Allergy and Asthma European Network (GA2LEN)
Sep 8, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·U DarsowUNKNOWN European Task Force on Atopic Dermatitis/EADV Eczema Task Force
Mar 24, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·A WollenbergUNKNOWN European Task Force on Atopic Dermatitis/EADV Eczema Task Force
Jun 22, 2005·Journal of the American Academy of Dermatology·David A Norris
Jun 22, 2005·Journal of the American Academy of Dermatology·Alice B Gottlieb
Apr 20, 2005·Dermatologic Clinics·Daniel N Sauder, Mona Z Mofid
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Sharon E Jacob, Mari Paz Castanedo-Tardan
Jul 22, 2004·Expert Opinion on Pharmacotherapy·Aditya K Gupta, Nataly Kogan
Oct 23, 2016·American Journal of Clinical Dermatology·Aditya K GuptaWilliam Abramovits
Mar 17, 2017·Journal of Cutaneous Medicine and Surgery·Julia N Mayba, Melinda J Gooderham
Dec 28, 2018·Expert Review of Clinical Immunology·Aisleen Diaz, Emma Guttman-Yassky
Jul 11, 2006·Current Allergy and Asthma Reports·Edward R Conner, Lisa A Beck
Oct 13, 2007·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Ryan BergFrank Litvack
Sep 7, 2006·Current Opinion in Allergy and Clinical Immunology·William Abramovits, Amy Perlmutter
Sep 29, 2011·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Aikaterini Thanou-StavrakiJohn B Harley
Apr 30, 2003·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·S Ständer, T A Luger
Aug 30, 2003·Expert Opinion on Drug Safety·Tsippora Shainhouse, Lawrence F Eichenfield
Jan 14, 2005·Journal of Cutaneous Medicine and Surgery·Daniel N Sauder
Jul 1, 2007·Expert Review of Clinical Immunology·David A Wrone, Daniel N Sauder
May 26, 2018·JAMA Dermatology·Thomas N Darling
May 14, 2020·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·S Salzmann, P Staubach
Nov 19, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·A WollenbergUNKNOWN European Task Force on Atopic Dermatitis/EADV Eczema Task Force

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.